BB Biotech's shares, which historically have traded at a double-digit premium relative to the net asset value of its underlying investment portfolio, now is priced in line with its NAV. When this has happened in the past, the premium has quickly rebounded.

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.